172 related articles for article (PubMed ID: 17101678)
1. Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
Zimhony O; Vilchèze C; Arai M; Welch JT; Jacobs WR
Antimicrob Agents Chemother; 2007 Feb; 51(2):752-4. PubMed ID: 17101678
[TBL] [Abstract][Full Text] [Related]
2. Analogs of the antituberculous agent pyrazinamide are competitive inhibitors of NADPH binding to M. tuberculosis fatty acid synthase I.
Sayahi H; Pugliese KM; Zimhony O; Jacobs WR; Shekhtman A; Welch JT
Chem Biodivers; 2012 Nov; 9(11):2582-96. PubMed ID: 23161636
[TBL] [Abstract][Full Text] [Related]
3. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
Zimhony O; Cox JS; Welch JT; Vilchèze C; Jacobs WR
Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.
Ngo SC; Zimhony O; Chung WJ; Sayahi H; Jacobs WR; Welch JT
Antimicrob Agents Chemother; 2007 Jul; 51(7):2430-5. PubMed ID: 17485499
[TBL] [Abstract][Full Text] [Related]
5. Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.
Bergmann KE; Cynamon MH; Welch JT
J Med Chem; 1996 Aug; 39(17):3394-400. PubMed ID: 8765523
[TBL] [Abstract][Full Text] [Related]
6. Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide.
Speirs RJ; Welch JT; Cynamon MH
Antimicrob Agents Chemother; 1995 Jun; 39(6):1269-71. PubMed ID: 7574514
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Mycobacterium smegmatis expressing the Mycobacterium tuberculosis fatty acid synthase I (fas1) gene.
Zimhony O; Vilchèze C; Jacobs WR
J Bacteriol; 2004 Jul; 186(13):4051-5. PubMed ID: 15205406
[TBL] [Abstract][Full Text] [Related]
8. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.
Zhang Y; Wade MM; Scorpio A; Zhang H; Sun Z
J Antimicrob Chemother; 2003 Nov; 52(5):790-5. PubMed ID: 14563891
[TBL] [Abstract][Full Text] [Related]
9. QSAR modeling of a set of pyrazinoate esters as antituberculosis prodrugs.
Fernandes JP; Pasqualoto KF; Felli VM; Ferreira EI; Brandt CA
Arch Pharm (Weinheim); 2010 Feb; 343(2):91-7. PubMed ID: 20099263
[TBL] [Abstract][Full Text] [Related]
10. Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro.
Wade MM; Zhang Y
J Antimicrob Chemother; 2006 Nov; 58(5):936-41. PubMed ID: 16950824
[TBL] [Abstract][Full Text] [Related]
11. Antimycobacterial activity of a series of pyrazinoic acid esters.
Cynamon MH; Klemens SP; Chou TS; Gimi RH; Welch JT
J Med Chem; 1992 Apr; 35(7):1212-5. PubMed ID: 1560435
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives.
Seitz LE; Suling WJ; Reynolds RC
J Med Chem; 2002 Dec; 45(25):5604-6. PubMed ID: 12459027
[TBL] [Abstract][Full Text] [Related]
13. Antimycobacterial activity of pyrazinoate prodrugs in replicating and non-replicating Mycobacterium tuberculosis.
Segretti ND; Simões CK; Corrêa MF; Felli VMA; Miyata M; Cho SH; Franzblau SG; Fernandes JPDS
Tuberculosis (Edinb); 2016 Jul; 99():11-16. PubMed ID: 27449999
[TBL] [Abstract][Full Text] [Related]
14. Iron enhances the antituberculous activity of pyrazinamide.
Somoskovi A; Wade MM; Sun Z; Zhang Y
J Antimicrob Chemother; 2004 Feb; 53(2):192-6. PubMed ID: 14729751
[TBL] [Abstract][Full Text] [Related]
15. The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD.
Sun Q; Li X; Perez LM; Shi W; Zhang Y; Sacchettini JC
Nat Commun; 2020 Jan; 11(1):339. PubMed ID: 31953389
[TBL] [Abstract][Full Text] [Related]
16. Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis.
Simões MF; Valente E; Gómez MJ; Anes E; Constantino L
Eur J Pharm Sci; 2009 Jun; 37(3-4):257-63. PubMed ID: 19491013
[TBL] [Abstract][Full Text] [Related]
17. Salicylanilide pyrazinoates inhibit in vitro multidrug-resistant Mycobacterium tuberculosis strains, atypical mycobacteria and isocitrate lyase.
Krátký M; Vinšová J; Novotná E; Stolaříková J
Eur J Pharm Sci; 2014 Mar; 53():1-9. PubMed ID: 24333643
[TBL] [Abstract][Full Text] [Related]
18. Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system.
Salfinger M; Crowle AJ; Reller LB
J Infect Dis; 1990 Jul; 162(1):201-7. PubMed ID: 2113074
[TBL] [Abstract][Full Text] [Related]
19. Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity.
Cynamon MH; Gimi R; Gyenes F; Sharpe CA; Bergmann KE; Han HJ; Gregor LB; Rapolu R; Luciano G; Welch JT
J Med Chem; 1995 Sep; 38(20):3902-7. PubMed ID: 7562923
[TBL] [Abstract][Full Text] [Related]
20. Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I.
Sayahi H; Zimhony O; Jacobs WR; Shekhtman A; Welch JT
Bioorg Med Chem Lett; 2011 Aug; 21(16):4804-7. PubMed ID: 21775138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
